Collaboration, License and Other Arrangements -Additional Information (Details) - USD ($) $ in Millions |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Acquired in-process research and development expenses | $ 0.5 | $ 19.8 |
| CRISPR JDCA | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Acquired in-process research and development expenses | $ 0.0 | 12.5 |
| Proceeds from upfront payment | $ 12.5 | |
| CRISPR | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Allocation of net profits and net losses, percent | 40.00% | |
| Collaborative arrangement, allocation of research and development expenses, percent | 40.00% | |